The lack of longitudinal models, such as thyroid cancer organoid systems or time-resolved in vivo experiments, limits our ability to mechanistically dissect how IGF2BP2 orchestrates dedifferentiation during tumor evolution phases. This evidence concerns the gene IGF2BP2 and thyroid gland carcinoma.